ARTICLE / CLIENT ALERT
DOJ and Postal Service bring first charges – and make first whistleblower payment – under new Whistleblower Rewards Program
February 10, 2026
Read time: 6 min
On January 29, 2026, the US Department of Justice (DOJ) and United States Postal Service announced a $1 million payment to a whistleblower for reporting information about a criminal antitrust violation. The payment is the first under the DOJ’s and Postal Service’s new Whistleblower Rewards Program.
The announcement is reminder of the importance of conducting comprehensive antitrust due diligence when engaged in mergers and acquisitions (M&A), building antitrust compliance into integration planning, and maintaining robust policies and procedures to detect and prevent antitrust violations across the enterprise.
What happened?
- The DOJ Antitrust Division, together with the Postal Service, announced its first whistleblower reward just six months after launching the Whistleblower Rewards Program in July 2025.
- The whistleblower reported information leading to criminal antitrust and fraud charges against EBLOCK, an online auction platform for used vehicles. EBLOCK resolved these charges through a deferred prosecution agreement, which requires EBLOCK to pay a $3.28 million criminal fine, cooperate with the DOJ Antitrust Division’s continued investigation and any future prosecutions related to the scheme, and implement an appropriate antitrust compliance program.
- The conduct began prior to EBLOCK’s November 2020 acquisition of Company A, which also operated an online auction platform for used vehicles. Before the acquisition, employees at Company A were engaged in a bid-rigging scheme with Company B, a used-auto wholesaler. As part of the scheme, Company A shared confidential bidding information with Company B and conspired with Company B to place fake bids on Company A’s platform to inflate the auction price legitimate buyers paid for used cars.
- The conduct slipped through cracks during the acquisition – EBLOCK did not conduct due diligence or integration in person – and went undetected on Company A’s separate, third-party maintained auction platform until January 2021. Once detected, EBLOCK attempted to end the conduct, but legacy Company A employees continued coordinating with Company B even after Company A’s auctions were finally migrated onto EBLOCK’s auction platform, all while hiding their efforts from EBLOCK. The conduct finally terminated in February 2022.
- The whistleblower will receive a $1 million payment, about 30% of EBLOCK’s fine.
What is the Whistleblower Rewards Program?
- Announced in July 2022, the Whistleblower Rewards Program is a partnership between the DOJ Antitrust Division and the Postal Service in which individuals who report information about criminal antitrust violations are eligible to receive 15% to 30% of resulting criminal recoveries that exceed $1 million.
- The DOJ seems to be using this program to target “hard-core” criminal antitrust violations of Section 1 of the Sherman Act: price fixing, bid rigging, and market allocation. It is worth noting, however, that whistleblowers can receive rewards for other criminal violations of Section 1, 2, and 3 of the Sherman Act, as well as related offenses, such as those that facilitate these activities or conduct that interferes with federal antitrust investigations or proceedings.
- Rewards under the program are available to individuals who voluntarily provide original information about the violation. Even those who were involved in the criminal activity are eligible, so long as they did not coerce another party to participate or were clearly the leader of the criminal activity.
- The violation must affect the Postal Service, such as by using US mail to send documentation related to the illegal activity. The harm to the Postal Service “need not be material,” indicating a low bar to meet this requirement.
- This announcement provides an early indication that the program is bearing fruit for the Antitrust Division. Omeed Assefi, deputy assistant attorney general for the Antitrust Division, remarked at a recent conference that the division is “already seeing a frenzy of people coming forward” under the Whistleblower Rewards Program.
What are the implications for companies?
- Act fast: The Whistleblower Rewards Program will place pressure on companies seeking leniency to accelerate their process for reviewing and self-reporting violations. “Remember,” Assefi warned, “the first company in an antitrust cartel that reports its collusion to the Antitrust Division might receive leniency, but the race is faster now, because employees and their attorneys are incentivized to blow the whistle and beat their companies to the Division’s doorstep.”
- Gear up: A plan for quick detection, investigation, and action with respect to antitrust misconduct can help companies get ahead of whistleblowers. Companies should develop clear and confidential internal mechanisms for employees to escalate potential antitrust violations so the company can take appropriate steps to timely investigate the conduct, implement necessary remedial actions, or even seek leniency from the DOJ.
- Check under the hood: It is important for companies engaging in M&A activity to be mindful of antitrust compliance during the acquisition process. Companies should conduct comprehensive antitrust due diligence before the acquisition, assess the potential for any anticompetitive activity (particularly in any separately maintained systems) at the target post-acquisition, and build antitrust training into integration plans.
- Schedule a tune-up: To prevent antitrust violations from going undetected – and from occurring in the first place – companies should design and implement effective compliance programs that are reasonable in relation to their size, resources, and unique exposure to antitrust risk. According to the DOJ’s November 2024 guidance, an appropriate compliance program meets the following basic requirements:
- Features policies and procedures designed to prevent antitrust violations;
- Fosters a culture of antitrust compliance through the example and encouragement of senior leadership;
- Assigns a senior leader, and, if needed, outside counsel, to implement a compliance program;
- Conducts periodic antitrust risk assessments;
- Develops an antitrust training program for all relevant employees; and
- Creates a reporting system that allows employees to confidentially and anonymously report potential antitrust violations and is designed to promptly respond.
The DOJ’s guidance also reminds companies that their compliance programs should not be static: Companies should update their compliance programs as their operations, the law, and industry practices evolve.

JPM briefing: Life sciences investors cautiously optimistic for 2026 and beyond
ARTICLE
JPM briefing: Life sciences investors cautiously optimistic for 2026 and beyond
February 9, 2026
Read time: 6 min
The life sciences investment climate is looking up, as industry adapts to challenging supply-side forces and AI makes inroads in healthcare.
The life sciences industry is poised for better times in 2026, according to speakers at the McDermott Forum, held on January 13, 2026, during the 44th annual J.P. Morgan Healthcare Conference. Hosted by McDermott Will & Schulte with knowledge partner Ernst & Young (EY) at the Ritz-Carlton San Francisco, the event featured insights from senior life sciences, investment, and policy leaders on a broad range of subjects, including merger and acquisition activity, trade policy, drug pricing, investment trends, and global health. Speakers pointed to renewed engagement from strategic buyers, private equity sponsors, and public market investors alike.
Here, McDermott and EY share key takeaways from the event.
Adapting to government changes
Regulatory oversight
The second Trump administration has taken a strong interest in oversight of the life sciences sector, with a particular focus on affordability and on-shoring and the industry has had to adapt quickly to many regulatory changes that have, at times, created market opportunities. After the first year of Trump’s second term, the industry has a clearer sense of what to expect and the overall cadence—its own form of normalization—though predictability remains limited. Respondents to a live poll at the forum said that the biggest source of uncertainty in life sciences today is political volatility and election dynamics (40%), followed by drug pricing and Medicare/Medicaid reforms (25%), and US Food and Drug Administration unpredictability (16%).
Scrutiny of drug pricing
The administration continues to pursue initiatives to lower drug prices, including a new most-favored nation (MFN) plan and a direct-to-consumer sales model. Pharmaceutical companies are responding by striking MFN deals with the federal government and can now move forward with a higher degree of confidence, having found some resolution to a major market change. Cutting out the middlemen could create new opportunities to access patients and increase sales volume.
Fate of executive orders
While the regulatory environment is improving in 2026, panelists noted that there is still uncertainty about the future. It’s unclear how many executive orders, such as those mandating MFN pricing with direct-to-consumer sales and providing incentives for reshoring domestic pharmaceuticals manufacturing to the US, will survive past the current administration. So making longer-term investment decisions around that dynamic may be challenging.
“We’re meeting at a moment when regulatory change is shaping nearly every corner of the life sciences sector, from how companies plan their pipelines to how investors calibrate risk.” – Paul Gadiock, McDermott Will & Schulte partner
Improved financial outlook
Private capital
Private capital, including private equity, venture capital, and crossover investors, continues to play a huge role in life sciences and healthcare broadly. Activity increased in the second half of 2025 and into early 2026. In the first week of January, more than $2 billion of private capital investment was announced in biopharma and MedTech. Most participants at the McDermott Forum (79%) predicted that life sciences investment activity will improve in 2026.
IPO rebound
Based on encouraging momentum in January, the initial public offering (IPO) market looks set to rebound from last year’s low, and ongoing interest rate cuts will further improve the outlook. The launch of several big-name IPOs outside the healthcare sector could initially divert investment away from other sectors but, if successful, could have a positive spillover effect for biotech.
Urgent need for mergers and acquisitions (M&A)
Given that patents for several blockbuster drugs are expiring and will lead to some $300 billion in revenue losses between 2028 and 2032, panelists foresee a strong demand for M&A. In a live forum poll, 40% of participants said that deal activity is picking up, but with smaller asset acquisitions rather than mega deals, and 40% said the “money is there but confidence isn’t fully back.” Buyers likely will be interested in a diverse array of therapeutic areas, but assets must be differentiated and relatively advanced clinically, panelists said.
AI’s growing impact in healthcare
More trial successes
Artificial intelligence (AI) is starting to make its mark on the industry, particularly in improving success rates of clinical trials. According to Pitchbook’s latest analysis, AI can help boost success rates from 52% to 80% in Phase I to II, and from 29% to 40% from Phase II to III, reducing costs in the process. As a result, expect more AI-powered drug discovery partnership deals.
Mass AI adoption
Healthcare’s adoption of technology is often slowed by regulatory constraints, but some applications, such as the use of scribes during patient visits, are proving very popular. Consumers have embraced AI, with an estimated 40 million asking health questions of ChatGPT every day. AI-enabled companies secured 54% of venture capital funding for digital health startups in 2025, up from 37% in 2024.
Winning in AI
The challenge for industry is how to develop AI tools with meaningful return on investment, not just hype experiments.
Bending the cost curve
Cost increases
Employers expect a 10% increase in costs to provide insurance coverage for their employees in 2026, which the panelists said is unsustainable. Investors are increasingly looking for solutions that give outcomes that can reduce costs in the healthcare system, while also improving the experience of plan members.
Consumer power
Consumers continue to become more empowered in a number of different ways. They are gaining personalized information through wearables and have more opportunities to obtain drugs without a doctor’s prescription or even insurance. Also, AI could make it easier to evaluate various services and their costs in a way that wasn’t possible 10 years ago. In short, shopping around for healthcare is getting easier.
The way forward
Despite the many supply-side pressures of recent years, including changes in trade policy, tariffs, and immigration, the global economy has proven resilient, with only a slight cooling in activity. The twin trends of low birthrates and an aging population will increase pressure to improve productivity through AI. EY-Parthenon Chief Economist Greg Daco noted: “If we are able to drive stronger productivity growth, we might be able to offset part of the demographic drag that is likely to be with us, not for just the next year, but for the next 50 years.”

Illinois lawmakers seek to expand scope of AG healthcare transaction review
ARTICLE / CLIENT ALERT
Illinois lawmakers seek to expand scope of AG healthcare transaction review
February 9, 2026
Read time: 4 min
On February 4 and 5, 2026, Illinois lawmakers introduced parallel bills (House Bill (HB) 5000 and Senate Bill (SB) 3463) that would amend Illinois’ healthcare transaction reporting framework to broaden the types of transactions – and the parties – required to provide advance notice to the Illinois attorney general (IL AG).
As we reported in a previous client alert, effective January 1, 2024, the IL AG began overseeing a broad array of transactions that involve healthcare entities. Under the Illinois Antitrust Act, any “covered transaction” between two or more healthcare facilities or provider organizations not previously under common ownership or contracting affiliation must provide at least 30 days’ notice to the IL AG before closing.
The proposed legislation would broaden the existing definition of “covered transaction” by replacing “between” with “involving.” This change is intended to capture transaction structures where the parties to the transaction are not themselves healthcare facilities or provider organizations, but the transaction nonetheless results in a change of control or common ownership of a healthcare facility or provider organization. By extending notice obligations to indirect owners, the changes proposed by the bills could increase transparency expectations and introduce new timing considerations for parties to covered transactions.
The proposed legislation would require notice not only from healthcare facilities and provider organizations, but also from entities that own or control, directly or indirectly, one or more of the healthcare facilities or provider organizations that would be under common ownership or affiliation following the transaction. The parallel bills explicitly contemplate transactions involving private equity companies.
The proposed legislation defines a “private equity company” as an entity that pools capital and acquires ownership interests, directly or indirectly, in Illinois healthcare entities, as well as in out-of-state healthcare entities that generate $10 million or more in annual revenue from patients that reside in Illinois.
The proposed legislation also introduces definitions for two undefined terms in the current notification statute:
- “Health care provider” means an individual or entity duly licensed or legally authorized to provide healthcare services.
- “Health care services” means healthcare services or products rendered or sold by a healthcare provider within the scope of the healthcare provider’s license or legal authorization. The term includes, but is not limited to, hospital, medical, surgical, dental, vision, and pharmaceutical services or products.
These new definitions would likely expand the types of reported transactions.
Even though the bills would not revise the “provider organization” definition, the new terms could indirectly influence how that definition is applied, particularly with regard to the concept of being in the “business of health care delivery or management.” By tying “health care services” explicitly to services or products rendered within the scope of a healthcare provider’s license, the bills could influence how parties and regulators assess whether certain arrangements fall outside the statute, particularly where parties might otherwise rely on “nonclinical” characterizations.
If either bill is enacted as proposed, the January 1, 2027, inoperative/repeal date affecting both the notice provisions and certain related change-of-ownership provisions would be removed, thereby extending the reporting framework beyond 2026.
The proposed bills would not add any framework for the scope of additional information that can be requested of the parties to a transaction or limit the time period in which a transaction can be effectively tolled.
If enacted, the changes to Illinois’ healthcare transaction reporting framework contemplated by the bills would apply to a broader segment of transactions, thereby requiring further analysis as part of deal planning and assessment of impact on transaction timelines, particularly for transactions involving layered ownership or nontraditional healthcare structures. The provision of the required notice to the IL AG is merely the beginning of the review process for a covered transaction, and if either of these bills is passed into law, that review would apply to additional Illinois healthcare transactions.
For more information or for assistance with HB5000 and SB3463, please contact the authors.

A newly devised clause to strengthen cross-border enforcement of monetary judgments
ARTICLE / CLIENT ALERT
A newly devised clause to strengthen cross-border enforcement of monetary judgments
February 9, 2026
Read time: 3 min
Enforcing monetary judgments across borders remains a significant challenge for international businesses. Even where a final court judgment has been obtained, recovery can be delayed or frustrated by inconsistent recognition regimes, lack of reciprocity, and practical difficulties in pursuing overseas assets.
In response to these challenges, McDermott Will & Schulte Partner, Hilton Mervis, has developed a new contractual mechanism designed to strengthen cross-border enforcement of monetary judgments. To help address this enforcement gap, parties may wish to introduce an arbitration clause to their contracts that combines the benefits of court litigation with the enforcement advantages of arbitration under the New York Convention.
The clause and how it works
Under the proposed clause, which was devised to address practical enforcement risks commonly encountered in cross-border disputes, parties would agree in advance that if a final court judgment for payment remains unpaid after a specified period, the judgment creditor may refer the matter to arbitration for a strictly limited purpose. The arbitral tribunal would not revisit the merits of the dispute, with its mandate confined to:
- confirming the existence of a final and binding court judgment;
- determining payment consequences of non-payment, including interest and costs; and
- ordering relief, including the provision of security.
Any resulting decision would take the form of an arbitral award capable of enforcement under the New York Convention.
Security as a key feature
A central feature of the clause is the ability for the tribunal to order security equivalent to the unpaid judgment debt, typically to be paid into court or a designated account within a defined timeframe. This is designed to reduce delay, mitigate asset dissipation risk, and provide leverage in jurisdictions where post-judgment remedies may be limited or slow.
A dual-track enforcement model
The newly devised clause is intended to complement rather than replace litigation. It preserves open justice and full court adjudication while providing an additional arbitration-based enforcement pathway where direct enforcement of foreign judgments is uncertain.
The clause is currently the subject of comparative analysis across more than 40 jurisdictions, examining both the validity of the clause under local law and the enforceability of resulting awards under the New York Convention. The results will be published in the forthcoming Commercial Litigation and Cross-Border Enforcement Law Over Borders Comparative Guide 2026, published by The Global Legal Post and edited by McDermott Will & Schulte Partner, Hilton Mervis.
Read more on The Global Legal Post.

New EU cybersecurity package: What the proposed reforms mean for companies operating in the EU
ARTICLE / CLIENT ALERT
New EU cybersecurity package: What the proposed reforms mean for companies operating in the EU
February 12, 2026
Read time: 12 min
On 20 January 2026, the European Commission unveiled a new EU cybersecurity package comprising (i) a proposal to revise the Cybersecurity Act (CSA2) and (ii) targeted amendments to the Network and Information Systems 2 (NIS2) Directive.
The package aims to strengthen the EU’s cyber resilience, reduce regulatory fragmentation, and address escalating information and communications technology (ICT) supply-chain risks. Both proposals will now enter trialogue negotiations with the EU Parliament and the European Council and are expected to undergo further refinement, with the Commission targeting political agreement by early 2027.
Once adopted, CSA2 will apply directly across the EU, while Member States will have one year to transpose the NIS2 amendments into national law.
The direction of travel is clear: The targeted NIS2 amendments are intended to facilitate compliance for in-scope entities and to enhance legal certainty. In parallel, CSA2 marks a structural shift. Cybersecurity certification is elevated from a voluntary quality label to a compliance and risk-management instrument, the European Union Agency for Cybersecurity (ENISA) is repositioned as a more operational actor, and ICT supply-chain security moves beyond procedural due diligence towards EU-level risk assessment and enforceable mitigation measures and, where necessary, restrictions.
Targeted NIS2 amendments: Greater legal certainty and convergence
Although presented as a simplification exercise, the proposed NIS2 amendments would amount to a substantive recalibration. The emphasis is on legal certainty and convergence, while formally retaining NIS2 as a minimum-harmonisation directive.
1. Clearer scope and more predictable entity classification
To reduce the compliance burden, the proposal introduces more precise and proportionate scope rules, including:
- Sector-specific clarifications and thresholds, notably:
- A 1 MW–generation capacity threshold for electricity producers
- Targeted refinements for the healthcare, hydrogen, and chemical sectors
- Inclusion of European Business Wallets providers, as well as entities identified as owners, managers, and operators of strategic dual-use infrastructure within the scope of NIS2.
- Creation of a new small midcap enterprise category. As a main rule, small midcap entities referred to in Annex I will be classified as important rather than essential, reducing supervisory intensity.
Impact for business:
- Companies operating close to NIS2 thresholds should reassess their classification and regulatory exposure once the legislative process is more advanced.
- Globally acting companies are likely to benefit from greater consistency across Member States, reducing conflicting supervisory outcomes.
2. Risk-management measures: Minimum harmonisation with real convergence
NIS2 remains a minimum-harmonisation instrument. However, where the Commission adopts implementing acts specifying technical, methodological, or sectoral risk-management measures under Article 21(5), Member States will no longer be permitted to impose further national requirements for those measures.
This effectively shifts the definition of core cybersecurity controls to the EU level.
Impact for business:
- The exposure to national gold-plating of baseline cybersecurity controls will be reduced.
- There will be greater predictability for cross-border compliance programmes and internal control frameworks.
- Chief information security officers and legal teams should expect more uniform supervisory benchmarks over time.
3. Cybersecurity certification as a compliance tool
The revised NIS2 Directive is explicitly aligned with CSA2’s reform of the European Cybersecurity Certification Framework (ECCF). Organisations will be able to rely on European cybersecurity certification schemes, including future entity-level cyber-posture certifications, to demonstrate compliance with NIS2 risk-management obligations.
Where certification demonstrates compliance with the requirements, competent authorities will not be allowed to subject the entity to security audits.
Impact for business:
- Certification will become a strategic compliance instrument, not merely a voluntary quality label.
- Multinational organisations may be able to reduce duplicative audits and supervisory demands across jurisdictions.
4. Supply-chain security: From questionnaire fatigue to standardisation
The Commission explicitly recognises that NIS2 supply-chain obligations have generated burdensome and inconsistent supplier questionnaires, often cascading obligations down the supply chain.
The amendments foresee EU-level guidance on supply-chain security, addressing an appropriate level of detail, structure, and format for such information requests.
Impact for business:
- Supplier due-diligence processes may become standardised across the EU.
- The pressure to cascade extensive compliance questionnaires to out-of-scope suppliers will be reduced.
- There will be greater clarity during negotiations for contractual cybersecurity obligations.
5. Ransomware reporting: Better data, built-in safeguards
The amendments to NIS2 would introduce a basis for more harmonised EU-wide data collection on ransomware incidents, including attack vectors and mitigation measures. Sensitive information, such as ransom payments, will be disclosed only upon request of the Computer Security Incident Response Team or the competent authority.
Impact for business:
- Reporting expectations will increase.
- Incident-response playbooks will need to reflect more structured EU-level reporting workflows.
6. EU representative: Scope expansion
The proposed replacement of Article 26(3) removes the express limitation to entities referred to in Article 26(1)(b), comprising digital infrastructure, digital providers, and managed (security) service providers. As a result, the obligation to designate an EU-based representative would apply to all essential and important entities not established in the EU but offering services within it, including providers of public electronic communications networks and publicly available electronic communications services.
Jurisdiction would attach to the Member State where the representative is established, except for electronic communications providers, which would continue to fall under the jurisdiction of the Member State in which they provide their services. Where no representative is designated, any Member State in which services are offered may initiate enforcement action for infringements of NIS2.
Impact for business:
- Compliance obligations for non-EU providers will expand, notably in the telecommunications and electronic communications sectors, which are not currently subject to a representative requirement.
- Non-EU entities operating in multiple Member States without a designated representative will have increased enforcement exposure.
- Representative designation will become more strategically important, because the location of the representative may determine the primary supervisory interface for most non-EU operators.
7. Postquantum cryptography: A regulatory horizon signal
As part of the national cybersecurity strategy, Member States will be required to adopt policies for the transition to postquantum cryptography (PQC), taking into account the transition timelines and relevant requirements set out in applicable EU legal acts and policies, with EU-level timelines targeting 2030 for critical use cases and 2035 for medium- and low-risk use cases.
Impact for business:
- PQC moves from a theoretical issue to a medium-term regulatory expectation.
- Companies with long-lived systems or encrypted data should factor PQC into technology road maps and procurement decisions.
CSA2: From dormant framework to operational instrument
CSA2 seeks to address the limited uptake of EU cybersecurity certification and to reinforce the EU’s capacity to manage strategic ICT risks.
It introduces three core pillars:
- A significantly strengthened ENISA
- A simplified and expanded ECCF
- An ICT supply-chain framework
8. The operationalisation of ENISA’s mandate
CSA2 clarifies ENISA’s role and assigns it concrete, delivery-oriented tasks across four clusters:
- Support for implementation of EU cyber law and policy
- Operational cooperation
- Cybersecurity certification and standardisation
- Implementation of the Cybersecurity Skills Academy
Impact for business:
- ENISA tools and guidance are likely to function as de facto compliance standards for national authorities.
- Increased EU coordination should reduce inconsistent national supervision for cross-border operators.
- Certification and skills frameworks will increasingly be used to evidence compliance, governance maturity, and operational readiness.
9. Certification: From a nice-to-have label to a compliance and market-access tool
CSA2 aims to make the ECCF more effective and more usable across the entire market, including certification for ICT products, services, and processes; managed security services; and the cyber posture of entities. European cybersecurity certification will continue to be voluntary, unless otherwise specified in EU or national law.
What changes in substance:
- A broader scope, including an entity-level cyber-posture concept.
- A stronger link between certification and compliance via presumption of conformity mechanisms where EU or national law recognises certification to demonstrate compliance.
Impact for business:
- Certification can become a differentiator (and in some contexts, a quasi-requirement), especially in regulated sectors.
- Where EU or national law provides presumption of conformity, certification can reduce duplicative audits and lower friction with multiple supervisors.
- Expect more request for proposals and vendor contracts to require – or reward – EU certification.
10. Trusted ICT supply-chain framework: EU-level mechanism to address nontechnical risk
A core CSA2 revision is the EU-level trusted ICT supply-chain framework to address nontechnical risks (e.g., jurisdiction to which a supplier of certain components is subject) in sectors of high criticality and other critical sectors covered by NIS2. It is designed to (i) identify key ICT assets in critical ICT supply chains and (ii) impose appropriate and proportionate mitigation measures on NIS2-covered entities.
The framework sits alongside (and does not displace) obligations under the Cyber Resilience Act and national rules implementing Article 21 NIS2, and it explicitly allows Member States to have and maintain higher supply-chain requirements if consistent with EU law.
11. Coordinated security risk assessments
CSA2 enables the Commission – or at least three Member States – to trigger EU-level coordinated security risk assessments through the NIS Cooperation Group. These assessments must identify key ICT assets of the respective supply chains; assess threat actors, vulnerabilities, and risk scenarios; and propose mitigation measures. As a rule, they must be completed within six months, with shorter timelines possible in urgent cases. Where the Commission considers that a significant cyber threat endangering the functioning of the internal market, it may conduct its own assessment after consulting Member States.
Based on these assessments, the Commission may identify key ICT assets by implementing act, taking into account their essential and sensitive functions, the potential for serious disruption or data exfiltration, supplier concentration risks, and the results of the risk assessments.
In parallel, CSA2 establishes a mechanism to address nontechnical risks linked to third countries. Where a third country is found to pose a serious and structural nontechnical risk to ICT supply chains – based on factors such as vulnerability disclosure laws or practices, lack of effective oversight, or substantiated malicious cyber activity – the Commission may designate that country as posing cybersecurity concerns. Entities established in, or controlled by, such countries or otherwise designated following a specific risk assessment may be classified as high-risk suppliers.
Impact for business:
- Companies should expect deeper scrutiny of supplier dependencies, ownership structures, and concentration risks.
- Certain suppliers or components may become legally constrained or unavailable, directly affecting sourcing strategies, cost structures, and deployment timelines.
- Robust asset and supply-chain mapping will become a prerequisite for compliance and risk management.
12. Binding mitigation measures and prohibitions
Following risk assessments, the Commission may impose binding mitigation measures by implementing act. These include transparency obligations and restrictions on data transfers, remote data processing from a third country, outsourcing and contractual arrangements, audited technical controls, personnel vetting, and diversification of supply of ICT components.
Where necessary, the Commission may go further and prohibit certain types of NIS2-covered entities from using, installing, or integrating ICT components from high-risk suppliers in key ICT assets, subject to transition and phase-out periods. Before adopting such measures, the Commission must assess potential risks and dependencies.
Impact for business:
- CSA2 enables a shift from assessment to operationally intrusive and enforceable controls.
- Expect concrete consequences in particular for IT architecture, outsourcing models, data flows, and supplier contracts.
- Exit strategies, diversification planning, and migration budgets will become essential compliance tools.
13. Exemptions: Limited flexibility under strict conditions
Entities established in or controlled by entities from a third country posing cybersecurity concerns may make a reasoned request to the Commission to be exempted. Exemptions require clear evidence of effective mitigation, may be time limited and conditional (e.g., audits and reporting), and are subject to fees. Decisions are recorded in a public register.
Impact for business:
- Exemptions may provide short-term relief where alternatives are unavailable but create delay, compliance overhead, and reputational exposure.
- Exemptions should be viewed as exceptional and temporary, not a long-term sourcing strategy.
14. Mandatory phase-out of high-risk suppliers
For mobile, fixed, and satellite electronic communications networks, CSA2 identifies key ICT assets and mandates the phase-out of components from high-risk suppliers. For mobile electronic communications networks, the phase-out period must not exceed 36 months from publication of the relevant high-risk supplier list; timelines for fixed and satellite networks will be set via implementing acts.
Impact for business:
- Telecom operators will face the clearest, most immediate outcome: mandatory replacement programmes with fixed deadlines.
- Significant capital expenditure, procurement, and service-continuity risks are likely, with downstream effects for customers.
Conclusion and recommended next steps for companies
Taken together, the proposed NIS2 amendments and CSA2 point to a clear change in direction in EU cybersecurity law, moving away from fragmented national approaches towards greater coordination and more harmonised supervision.
For businesses, cybersecurity is increasingly treated as a matter of enterprise risk management and corporate governance rather than a purely technical issue. At this stage, close monitoring of the legislative process is important. The proposal – including scope thresholds, the use of EU-level implementing acts, and the role of certification – remain subject to negotiation and may still evolve in ways that affect compliance planning and operational choices.
Organisations that follow these developments early will be better placed to adjust once the framework is finalised.

Trending in Telehealth: January 2026
ARTICLE
Trending in Telehealth: January 2026
Feb 6, 2026
Read time: 5 min
Trending in Telehealth highlights monthly state legislative and regulatory developments that impact healthcare providers, telehealth and digital health companies, pharmacists, and technology companies that deliver and facilitate the delivery of virtual care.
Trending in January:
- Expanded use of telehealth across specific care settings, including reproductive health, maternity support services, controlled substance prescribing, and crisis care
- Telehealth compliance and disciplinary standards
- Broader use of out-of-state registration pathways and licensure compacts to support interstate practice
A CLOSER LOOK
Proposed legislation & rulemaking:
- In New York, S 1438 passed the first chamber. The bill would establish a program within the New York State Department of Health to train healthcare practitioners in abortion and related reproductive care services, including telehealth delivery of such services.
- In Vermont, HB 84 passed the first chamber. It would amend the state’s telehealth law, which currently prohibits a healthcare provider or patient from recording a telemedicine consultation, to allow telehealth appointments to be recorded with both patient and provider consent.
- In Wisconsin, SB 214 passed both chambers. If signed by the governor, the bill would allow out-of-state healthcare providers to register with the Wisconsin Department of Safety and Professional Services (DSPS) to provide telehealth services to patients in Wisconsin in lieu of requiring licensure or other registration in the state. Registered providers could provide services within the scope of practice established under Wisconsin law and would be subject to disciplinary action in Wisconsin. Registration requirements would include holding an active, unencumbered out-of-state credential that authorizes similar services in the provider’s home state; having no recent disciplinary history; designating an in-state registered agent; and maintaining malpractice coverage for services provided to Wisconsin patients. The law would prohibit registered telehealth providers from opening an in-state physical practice without obtaining a Wisconsin credential and would require DSPS to publish a list of registered telehealth providers.
- In New Mexico, HB 13 and HB 11 each passed the first chamber. They would adopt the Occupational Therapy Licensure Compact and the Audiology and Speech Language Pathology Compact, respectively.
- A Washington proposed rule would permit state Medicaid reimbursement for certain maternity support services delivered through telemedicine, including an initial screening, replacing requirements that such services be provided in person.
- In New Hampshire, a proposed rule would introduce an option for participants in the Choices for Independence program to elect to receive services via telehealth subject to certain requirements, including that the provider assess the appropriateness of telehealth delivery for the participant and ensure that the participant has adequate access to any necessary technology before services are provided.
- In Wisconsin, a proposed rule would impose additional requirements on crisis care facilities. The rule would mandate the adoption of policies addressing telehealth, artificial intelligence, and consultation via electronic communication and would require facilities to maintain adequate 24/7 staffing, including through the use of telehealth.
Finalized legislation & rulemaking activity:
- New Jersey passed, and the governor signed, SB 2283, which establishes a pilot program to support research into the therapeutic use of psilocybin for behavioral health conditions and to assess the feasibility of a regulated statewide delivery system. The law authorizes selected hospitals to administer psilocybin therapeutically, including via telehealth when consistent with the applicable standard of care, and to collect clinical outcome data to evaluate safety and efficacy.
- North Dakota enacted HB 1622, joining the Physician Assistant Licensure Compact and establishing the framework for the state’s participation, administration, and enforcement of the compact.
- The Washington State Board of Nursing adopted a rule requiring nurses who provide clinical services via telemedicine to complete specified state-mandated telemedicine training for healthcare professionals, consistent with a statutory requirement effective January 1, 2021.
- Maryland adopted a rule that expands the conditions under which a telehealth practitioner may prescribe certain controlled substances. Under the rule, a telehealth practitioner may prescribe certain Schedule II opiates for the treatment of pain when a bona fide practitioner-patient relationship has been established, provided the practitioner maintains ongoing responsibility for the patient’s assessment, care, and treatment and an in-person assessment has previously been conducted by the practitioner or another provider within the same group practice.
- Florida adopted rules updating the disciplinary guidelines of the Board of Physical Therapy Practice and the Board of Hearing Aid Specialists to apply rules regarding patient overpayments and refunds to telehealth registrants.
Why it matters:
- States are expanding telehealth access while tightening guardrails. Developments reflect ongoing efforts by states to expand telehealth access through licensure compacts, out-of-state registration pathways, Medicaid coverage, and service flexibility while simultaneously imposing clearer requirements around training, staffing, and professional accountability.
- States are leveraging telehealth to address policy priorities. Legislatures and regulators are using telehealth to support access to reproductive health services, maternity support, crisis care, and services for specialized populations, signaling telehealth’s continued integration into mainstream healthcare delivery.
Telehealth is an important development in care delivery, but the regulatory patchwork is complicated. The McDermott Will & Schulte digital health team works alongside the industry’s leading providers, payors, and technology innovators to help them enter new markets, break down barriers to delivering accessible care, and mitigate enforcement risk through proactive compliance.

New York governor proposes changes to healthcare transaction rules
ARTICLE / CLIENT ALERT
New York governor proposes changes to healthcare transaction rules
February 6, 2026
Read time: 5 min
On January 20, 2026, New York Governor Kathy Hochul introduced legislation that would significantly modify New York’s material transaction notice requirements for certain healthcare transactions. The proposed legislation would add new disclosure obligations, introduce a deeper review process, and require multiyear reporting after a transaction closes. A final decision on the legislation will likely be made in April or May 2026. If passed, the new requirements would take effect in one year.
Why it matters
- The proposed legislation would create uncertainty around closing timeframes, potentially delaying transaction closings by months.
- The regulatory notice and review process would become more complex and burdensome for transacting parties and their affiliates.
- New disclosures would be required from certain investors in healthcare entities, both in connection with the transaction and for years thereafter.
Preliminary review and additional disclosures
Currently, the New York material transactions law does not expressly require or authorize the New York State Department of Health (DOH) to review notices of material transactions involving healthcare entities beyond evaluating the completeness of the notices. The governor’s proposed legislation would require DOH to conduct a “preliminary review” of material transactions and allow DOH to require any “party to a transaction” or “person with control” over such a party to submit additional documents and information as may be necessary to assess the transaction and its impacts, or to verify the information submitted.
The legislation would require two additional disclosures to be submitted along with the initial notice:
- Healthcare entity closures and reductions. A detailed description of any closed operations, closing operations, or substantial reductions in services that occurred at a healthcare entity owned by a party to the proposed transaction, or a person with control of such party, in the past three years.
- Real estate arrangements. Any documents related to any sale-leaseback, mortgage, lease arrangement, or “other payments associated with real estate” that are components of the transaction.
Cost market impact review
If a proposed transaction “is valued at” $100 million or more, the legislation would authorize DOH to perform a cost and market impact review (CMIR) of the transaction and to require the parties to delay the transaction closing for up to 180 days after DOH completes its preliminary review. The legislation would also authorize DOH to perform a CMIR if it “reasonably believes” that a transaction may negatively impact cost, quality, access, health equity, or competition, even if the transaction “is valued at” less than $100 million.
The calculation of the proposed CMIR threshold differs from the existing measurement for “de minimis” transactions. Whereas the current $25 million de minimis threshold is measured based on the increase in gross in-state revenue by a healthcare entity, the proposed $100 million threshold for a CMIR would instead be based on how “the transaction is valued,” which is undefined and unexplained in the legislation.
Five-year annual reporting
The legislation would require the “parties to a material transaction” to notify DOH annually for five years post-closing of certain factors and metrics necessary to assess the transaction’s impacts on cost, quality, access, health equity, and competition. DOH may require additional information from the transacting parties or entities that control the “parties to the transaction,” as well as persons with control over a “transaction party.” As proposed, the annual reporting requirement would be retroactive to all historic material transactions that have been reported since the inception of the original material transactions law.
Key takeaways
- The governor’s proposals will be subject to months of legislative scrutiny and may be amended or rejected by the New York legislature.
- If the legislation is enacted as proposed, DOH would have greater authority to scrutinize material transaction notices before deeming them complete, potentially delaying the notice and closing processes.
- Given the lack of clarity in key terms and concepts in the proposed legislation, stakeholders would need to interpret the terms and concepts themselves until DOH issued regulations or guidance setting forth its interpretations. That process could take months or years.
- Under the legislation, controlling affiliates of healthcare entities (including certain owners of physician management services) would be subject to certain disclosure requirements.
- If the new CMIR threshold is enacted, it would significantly delay large transactions ($100 million or more) and add greater uncertainty around closing timelines for smaller transactions. The New York State Legislature rejected the governor’s similar CMIR proposal last year.
We will continue to monitor the process and provide updates as they become available. If you have questions or would like to discuss any issues related to this proposed legislation, contact your regular McDermott Will & Schulte lawyer or one of the authors.
Olivia Andrews and Ashley Anumba, law clerks in the New York office, also contributed to this article.

Case exterminated too soon: DTSA and CFAA claims survive
ARTICLE
Case exterminated too soon: DTSA and CFAA claims survive
Feb 5, 2026
Read time: 4 min
The US Court of Appeals for the Tenth Circuit partially reversed and partially affirmed a series of district court rulings arising from alleged corporate espionage between competitors in the pest control industry. The decision clarifies the scope of recoverable “loss” under the Computer Fraud and Abuse Act (CFAA) after Van Buren and underscores that causation requirements under the Defend Trade Secrets Act (DTSA) and state trade secret law depend on the remedy sought. Moxie Pest Control LLC, et al. v. Kyle Nielsen, et al., Case No. 24-4076 (10th Cir. Jan. 21, 2026) (Hartz, Moritz, Rossman, JJ.)
Moxie sued rival Aptive Environmental, alleging that Aptive employees bribed current and former Moxie sales representatives to obtain confidential sales data stored in Moxie’s password-protected SalesRoutes system. According to Moxie, Aptive used this data (particularly sales leaderboards) to recruit door-to-door sales representatives by portraying Aptive as the more lucrative employer. Moxie brought claims under the CFAA, Racketeer Influenced and Corrupt Organizations (RICO) Act, DTSA, and Utah’s Uniform Trade Secrets Act (UTSA).
The district court dismissed Moxie’s CFAA claim at the pleading stage, denied motions to compel broad damages discovery, and granted Aptive summary judgment on the RICO, DTSA, and UTSA claims based on a lack of causation. Moxie appealed.
CFAA claim reinstated
The Tenth Circuit found that the district court erred in dismissing Moxie’s CFAA claim for failure to plead a qualifying “loss.” The district court had interpreted Van Buren v. United States as requiring plaintiffs to allege a technological harm, such as damage to data or systems, to recover under the CFAA. The Tenth Circuit rejected that interpretation, explaining that Van Buren addressed what conduct constitutes a CFAA violation, not the scope of recoverable loss once a violation has occurred.
Under the statute’s plain language, “loss” includes reasonable costs incurred in responding to an offense or conducting a damage assessment. Moxie’s allegations that it spent more than $5,000 investigating the unauthorized access (specifically identifying the perpetrators, methods, and scope of access) fell squarely within that definition. The Tenth Circuit emphasized that investigative costs aimed at understanding the breach itself are recoverable, even absent data corruption or system impairment.
Discovery rulings affirmed
The Tenth Circuit affirmed the district court’s denial of Moxie’s motions to compel expansive damages discovery. While acknowledging that some requested information could be relevant, the Court concluded that the district court acted within its discretion by limiting initial disclosures and inviting more targeted follow-up discovery. Moxie’s failure to pursue narrower discovery after the district court’s ruling weighed against a finding of abuse of discretion.
Trade secret and RICO claims
The Tenth Circuit agreed that Moxie failed to establish causation sufficient to sustain its RICO claim or to recover unjust-enrichment damages under the DTSA and UTSA. Evidence showing that Aptive sought Moxie’s data, used it in recruitment meetings, and experienced revenue growth during the same period amounted to correlation, not proof that the misappropriation caused Aptive’s profits. Without evidence tying the stolen data to actual financial gain, unjust-enrichment theories failed.
However, the Tenth Circuit found that the district court erred by treating the lack of causation as fatal to all DTSA and UTSA claims. Unlike unjust enrichment, other remedies (such as reasonable royalties and injunctive relief) do not require proof that misappropriation caused realized damages. Reasonable royalties, in particular, function as a hypothetical licensing measure when traditional damages are difficult to prove. Because the district court did not analyze the viability of these alternative remedies, summary judgment on the DTSA and UTSA claims was premature.
Practice note: The decision reinforces that CFAA “loss” remains broader than technological damage and highlights the importance of remedy-specific causation analysis in trade secret cases. Claims for injunctive relief and reasonable royalties may survive even when plaintiffs cannot show that misappropriation directly caused financial harm.

CMS indefinitely suspends submission of SNF Attachment for Medicare enrollment
ARTICLE / CLIENT ALERT
CMS indefinitely suspends submission of SNF Attachment for Medicare enrollment
February 4, 2026
Read time: 3 min
Skilled nursing facilities (SNFs) have long been required to report ownership and managerial control information to Medicare. Those disclosure obligations have been substantially broadened with the introduction of the CMS-855A SNF Attachment, which requires disclosure of information from additional disclosable parties (ADPs) who provide certain services to SNFs or exercise specified forms of control over them. However, after delaying the submission deadline twice, the Centers for Medicare & Medicaid Services (CMS) has now indefinitely suspended the SNF Attachment deadline.
As discussed in a prior client alert, on November 17, 2023, CMS published the final rule, Medicare and Medicaid Programs; Disclosures of Ownership and Additional Disclosable Parties Information for Skilled Nursing Facilities and Nursing Facilities; Medicare Providers’ and Suppliers’ Disclosure of Private Equity Companies and Real Estate Investment Trusts (See 88 FR 80141) (the Final Rule). In addition to other disclosure requirements, the Final Rule implemented disclosure requirements set forth in the Affordable Care Act, which requires SNFs to disclose information on ADPs as part of their Medicare enrollment.
In 2024, CMS released a new SNF Attachment and subregulatory guidance document, which provided SNFs with guidance and frequently asked questions related to the completion of the SNF Attachment.
This guidance document has been updated over time, with the most recent updates confirming there is no deadline to submit the SNF Attachment. The suspension applies to all SNFs that had a pending initial, revalidation, reactivation, or change of ownership application as of October 1, 2024, and were asked to submit the SNF Attachment. CMS has indicated it will provide additional information in future updates, but it remains to be seen whether CMS will modify its forms or its guidance regarding ADP disclosures.
In its guidance, CMS encourages SNFs to make at least one edit to any pending application in the Provider Enrollment, Chain, and Ownership System every 120 calendar days to prevent the application from being deleted for inactivity. Applications that are “Opened for Corrections” must be submitted within 20 days, and applications that are “Rejected” must be reopened within 60 days, and modified every 120 days thereafter, to prevent deletion.
Takeaways
Although the submission deadline has been indefinitely suspended, the Final Rule that implemented the ADP reporting obligations remains an active regulation. SNFs should monitor CMS updates for further developments in the submission of the SNF Attachment and, if a deadline is implemented, anticipate working closely with ADPs to secure the required information in accordance with CMS guidance.

IRS roundup: January 13 – January 20, 2026
ARTICLE
IRS roundup: January 13 – January 20, 2026
Feb 3, 2026
Read time: 4 min
Check out our summary of significant Internal Revenue Service (IRS) guidance and relevant tax matters for January 13, 2026 – January 20, 2026.
January 13, 2026: The IRS released Notice 2026-12, which provides the 24-month average corporate bond segment rates for January 2026, the yield curve and segment rates for single-employer plans, and the 30-year Treasury securities interest rates.
January 14, 2026: The IRS released Notice 2026-11, which provided interim guidance on the additional first-year depreciation deduction under Section 168(k) and announced the IRS’s intent to issue proposed regulations that would implement it. The One Big Beautiful Bill Act (OBBBA) created the permanent 100% additional first-year depreciation deduction for eligible depreciable property acquired after January 19, 2025. The notice advises taxpayers that they may generally continue to rely on the existing regulations governing the additional first-year depreciation deduction. The notice also outlines the criteria for determining whether depreciable property qualifies for the deduction and provides rules for calculating the allowable amount of the deduction under the OBBBA. The notice provides guidance on the addition of certain qualified sound recording productions that the OBBBA added as property that may qualify for the additional first-year depreciation deduction under Section 168(k)(2).
January 15, 2026: The IRS released Revenue Ruling 2026-3, which provides the February 2026 applicable federal rates.
January 15, 2026: The IRS released Notice 2026-13, which issued guidance updating the safe harbor explanations for retirement plans to reflect tax law changes implemented after Notice 2020-62 was issued on August 6, 2020. Notice 2026-13 modifies two safe harbor explanations that retirement plan administrators may use to satisfy the requirement under Section 402(f) to provide certain information to recipients of eligible rollover distributions. One safe harbor explanation applies to distributions that are not from a designated Roth account, and the other applies to distributions from a designated Roth account. The notice also clarifies changes to the 10% additional tax on early withdrawals from retirement plans, updates to the required minimum distribution rules for surviving spouses, and the increased age used to determine the required beginning date for required minimum distributions.
January 15, 2026: The IRS released Revenue Procedure 2026-8, which provided updated procedures for obtaining recognition of exemption from federal income tax on a group basis for organizations described in Section 501(c) that are affiliated with and under the general supervision or control of a central organization. The revenue procedure relieves subordinate organizations included in a group exemption letter from filing their own exemption applications. It also sets forth updated procedures a central organization must follow to maintain a group exemption letter.
Notice 2020-36 previously suspended the IRS’s acceptance of group exemption letter applications as of June 17, 2020, pending issuance of a final revenue procedure. This final revenue procedure has now been issued in the form of Revenue Procedure 2026-8, which states that the IRS will resume accepting applications for group exemption letters after January 20, 2026, the date of its publication. The revenue procedure further requires that group applications be submitted electronically on Form 8940, along with all information, documentation, and materials required by Form 8940 and its instructions.
January 15, 2026: The IRS released Notice 2026-8, which discussed the comments received in response to the proposed revenue procedure set forth in Notice 2020-36 regarding the group exemption letter program. The notice addressed modifications made to the proposed revenue procedure in response to the comments and other significant revisions made to the proposed revenue procedure, all of which were incorporated into the final regulations promulgated in Revenue Procedure 2026-8.
January 15, 2026: The IRS released Revenue Ruling 2026-4, which examines whether Alaska Railroad’s bonds for building infrastructure related to the process of extracting, processing, liquifying, and transporting natural gas qualify as tax-exempt treatment under Section 103(a). The revenue ruling discusses the statutory framework governing tax-exempt bonds under Sections 141 through 150.
January 20, 2026: The IRS released Tax Tip 2026-04, which describes recent changes to Qualified Opportunity Zones (QOZs) that enhance tax incentives for taxpayers investing in rural areas. Tax Tip 2026-04 made two notable updates: changing the definition of “rural areas” and modifying the substantial improvement threshold for improvements to property located in a QOZ, but only where that property is entirely in a rural area.
The IRS also released its weekly list of written determinations (e.g., Private Letter Rulings, Technical Advice Memorandums, and Chief Counsel Advice).
